Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Pipeline Review, H2 Pharmaceutical Research Report 2017

Posted on 2017-08-25 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, US, 2017-Aug-25 — /EPR Network/ —Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Pipeline Review, H2 2017”. Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Cancer/Testis Antigen 1 is a protein encoded by CTAG1A gene is an antigen that is over expressed in many cancers but that is also expressed in normal ovary and testis tissues which makes it a good candidate for a cancer vaccine.

Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305502

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 6 and 4 respectively. Similarly, the universities portfolio in Phase I stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Fallopian Tube Cancer, Metastatic Melanoma, Soft Tissue Sarcoma, Lung Cancer, Metastatic Ovarian Cancer, Synovial Sarcoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Melanoma, Metastatic Breast Cancer, Myelodysplastic Syndrome, Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Advanced Malignancy, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Bladder Cancer, Ewing Sarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Myxoid Liposarcoma, Neuroblastoma, Oligodendroglioma, Osteosarcoma, Rhabdomyosarcoma, Round Cell Liposarcoma, Sarcomas, Solid Tumor, Transitional Cell Cancer (Urothelial Cell Cancer) and Uterine Cancer.

The latest report CancerTestis Antigen 1 – Pipeline Review, H2 2017, outlays comprehensive information on the Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)
– The report reviews Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics and enlists all their major and minor projects
– The report assesses Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Browse Full Report With TOC: http://www.marketresearchhub.com/report/cancertestis-antigen-1-autoimmunogenic-cancertestis-antigen-ny-eso-1-or-cancertestis-antigen-61-or-l-antigen-family-member-2-or-ctag1a-or-ctag1b-pipeline-review-h2-2017-report.html

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Overview 7
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 14
Products under Development by Universities/Institutes 19
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Therapeutics Assessment 21
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Companies Involved in Therapeutics Development 25
Boehringer Ingelheim GmbH 25
Celldex Therapeutics Inc 26
GlaxoSmithKline Plc 27
Immune Design Corp 28
ImmunoFrontier Inc 29
Sanofi Pasteur SA 29
Scancell Holdings Plc 30
Vault Pharma Inc 30
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Drug Profiles 31
BI-1361849 – Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
CDX-1401 – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology – Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CMB-305 – Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
CMB-305 + G-100 – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
CUE-102 – Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
CYN-101 – Drug Profile 43
Product Description 43
Mechanism Of Action 43

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1305502

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick